Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 17,818 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 3 Clear all

Conditions: Hepatic Impairment
Interventions: JNJ-53718678; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Healthy Participants
Interventions: TMC435, Atorvastatin, Simvastatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Rheumatoid Arthritis
Interventions: Lutikizumab, Placebo, Ravagalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 49
States / cities: Peoria, Arizona • Jonesboro, Arkansas • Beverly Hills, California + 42 more

Conditions: Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions: TransCon PTH, Placebo; Combination Product
Lead sponsor: Ascendis Pharma Bone Diseases A/S; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 6 more

Conditions: Psoriasis
Interventions: BMS-986165, Placebo, Apremilast; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 67
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 57 more

Conditions: Metastatic Cancer, Cancer, Solid Tumor
Interventions: BP31510 monotherapy, BP31510 in combination with chemotherapy; Drug
Lead sponsor: BPGbio; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Sunnyvale, California • New York, New York • Houston, Texas

Conditions: Migraine
Interventions: Erenumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 955 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 59
States / cities: Phoenix, Arizona • Anaheim, California • Encino, California + 55 more

Conditions: Glioblastoma
Interventions: L19TNF, Lomustine; Drug
Lead sponsor: Philogen S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 4 more

Conditions: Endometriosis
Interventions: PF-02413873 100 mg QD, PF-02413873 1500 mg QD, PF-02413873 20 mg QD, PF-02413873 500 mg QD, PF-02413873 Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: New Haven, Connecticut • Overland Park, Kansas

Conditions: Hematologic Diseases, Acute-graft-versus-host Disease, Leukemia, Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma
Interventions: Sirolimus, Mycophenolate mofetil (MMF), Carmustine, Etoposide, Cyclophosphamide (Cyclo, CY), FTBI; Drug
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 60 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Intracerebral Hemorrhage, Hypertension, Stroke
Interventions: nicardipine; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 12
States / cities: Los Angeles, California • Kansas City, Kansas • Boston, Massachusetts + 8 more

Conditions: Schizophrenia
Interventions: LB-102; Drug
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Gadopentetate dimeglumine (Magnevist, BAY86-4882), Moxifloxacin (BAY12-8039), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: degarelix, enzalutamide, trametinib, dasatinib; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression, Menopause, Vasomotor Disturbance, Hot Flashes, Sleep
Interventions: vortioxetine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: enalapril maleate, quality-of-life assessment; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 8 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 55
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 43 more

Conditions: Womens Health, Menstrual Symptoms
Interventions: Effera® (human equivalent lactoferrin), Placebo; Dietary Supplement · Other
Lead sponsor: Helaina Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: San Francisco, California

Conditions: HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasm
Interventions: Topical ABI-1968 cream; Drug
Lead sponsor: Antiva Biosciences; Industry
Eligibility: 27 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rheumatoid Arthritis
Interventions: SAR441566; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Glendale, California

Conditions: Dyslipidemia
Interventions: AZD0780, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 14
States / cities: Huntsville, Alabama • Lincoln, California • Palm Springs, California + 11 more

Conditions: Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
Interventions: Pexidartinib, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 19
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions: Vorinostat, Niacinamide, Etoposide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: GLWL-01, Part A, Placebo, Part A, GLWL-01, Part B, Placebo, Part B, GLWL-01, Part C, Placebo, Part C; Drug
Lead sponsor: GLWL Research Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Tempe, Arizona • Chula Vista, California • Miami, Florida + 1 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
Interventions: BXCL701; Drug
Lead sponsor: Eric Stephen Winer, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study of JNJ-53718678 in Participants With Hepatic Impairment

A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Antihypertensive Treatment in Acute Cerebral Hemorrhage

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Vortioxetine for Menopausal Depression

Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer

Effera Dose Response: Women's Health

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome